Suven Life Sciences Q2 Results FY27: Net Loss Rs 106.94 Cr, Revenue Rs 1.20 Cr, Operating Loss Rs 110.92 Cr
- November 5, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Suven Life Sciences Q2 Results FY27 were declared on 5 November 2026 on a Consolidated basis. The quarterly results show revenue of Rs 1.20 Cr, up 30.43% year on year from Rs 0.92 Cr. Net loss was Rs 106.94 Cr against a net loss of Rs 77.31 Cr a year earlier, a YoY change of -38.33% as reported. Operating Profit was a loss of Rs 110.92 Cr against a loss of Rs 79.77 Cr.
Suven Life Sciences Ltd (SUVEN) Q2 Results FY27 announced on 5 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated results with revenue of Rs 1.20 Cr and a net loss of Rs 106.94 Cr, and Suven Life Sciences Q2 Results FY27 are measured against the same quarter a year earlier. Revenue is higher on that comparison, while the net loss is larger.
This results analysis covers the financial highlights, business drivers, outlook and risks behind the Suven Life Sciences Q2 Results. The Financial Highlights table that follows places the Consolidated figures beside the year-earlier quarter, so every reported number is visible before the discussion starts.
Click Here – Get Free Investment Predictions
Suven Life Sciences Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 1.2 Cr | Rs 0.92 Cr | +30.43% YoY |
| Operating Profit | Rs -110.92 Cr | Rs -79.77 Cr | -39.05% YoY |
| Net Profit (PAT) | Rs -106.94 Cr | Rs -77.31 Cr | -38.33% YoY |
Source: company filing for Suven Life Sciences Q2 Results FY27, 5 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Suven Life Sciences Q2 Results: What Stands Out
- Revenue of Rs 1.20 Cr grew 30.43% YoY from Rs 0.92 Cr, so the consolidated results show a larger top line than the year-earlier quarter.
- Operating Profit was a loss of Rs 110.92 Cr against a loss of Rs 79.77 Cr, and Suven Life Sciences Q2 Results FY27 record a YoY change of -39.05% as reported.
- Net loss of Rs 106.94 Cr compares with a net loss of Rs 77.31 Cr a year earlier, a YoY change of -38.33% as reported.
- Net profit margin narrowed to -8911.7% from -8403.3% in the comparison quarter.
- Return on capital employed improved to -78.71% in FY26 from -84.51% in FY25, while the company is almost debt free.
Suven Life Sciences Q2 Results FY27: Performance Analysis
Suven Life Sciences Q2 Results FY27 show revenue higher and both loss lines larger than the year-earlier quarter. Revenue grew 30.43% YoY to Rs 1.20 Cr, the Operating Profit loss moved to Rs 110.92 Cr and the net loss reached Rs 106.94 Cr, so the results analysis shows the bottom line moving to a deeper loss.
In rupee terms, revenue moved from Rs 0.92 Cr to Rs 1.20 Cr, while the net loss moved from Rs 77.31 Cr to Rs 106.94 Cr. Read together in the Suven Life Sciences Q2 Results figures, this is why the net profit margin narrowed from -8403.3% to -8911.7%, since the loss is very large against a small revenue base.
Investors will watch whether later quarterly results keep the same YoY growth pattern in revenue on a consolidated basis. Univest readers can follow each new declaration through the Univest Screener. The quarterly results analysis now turns to the business factors that were disclosed.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis begins with revenue, which grew 30.4% year on year to Rs 1.20 Cr in the latest quarter. This is the first disclosed factor and the base for the loss lines discussed in the risks.
Debt Position – The company is almost debt free, with a debt-to-assets ratio of 0.00 in FY26. This is a second disclosed factor that Suven Life Sciences Q2 Results FY27 place beside the revenue figure.
Return on Capital Employed – Return on capital employed improved to -78.71% in FY26 from -84.51% in FY25. This disclosed ratio is the third factor, and it frames the quarterly results from the capital side.
FY27 Outlook After Suven Life Sciences Q2 Results
This results analysis keeps to the disclosed figures. FY27 full-year consolidated results will depend on the quarters still to be declared and on the sector conditions disclosed over that period, and a net loss of Rs 106.94 Cr is one data point in that sequence. Later declarations remain the source for any change.
Suven Life Sciences Q2 Results FY27 will be compared with the next declarations, where revenue, Operating Profit and net profit will show how the year develops. Readers can follow those figures in the Univest app. The risks attached to this quarter’s numbers follow below.
Key Risks to Watch After Suven Life Sciences Q2 Results FY27
Net Loss in the Latest Quarter
The company reported a net loss of Rs 106.94 Cr in the latest quarter. This is the first risk to watch, because the loss is larger than the Rs 77.31 Cr loss in the year-earlier quarter.
Net Profit Margin
Net profit margin narrowed to -8911.7% from -8403.3% in the comparison quarter. Suven Life Sciences Q2 Results FY27 therefore show a loss that is very large against the revenue base.
Return on Equity
Return on equity was low at -101.80% in FY26. Investors will watch whether later quarters change this ratio.
Return on Capital Employed
Return on capital employed was modest at -78.71% in FY26, even though it improved from -84.51% in FY25.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Suven Life Sciences Q2 Results FY27 record consolidated revenue of Rs 1.20 Cr and a net loss of Rs 106.94 Cr for the July to September 2026 quarter. Revenue grew 30.43% YoY and the net loss moved from Rs 77.31 Cr to Rs 106.94 Cr, which are the main facts in the quarterly results. Anyone reading the Suven Life Sciences Q2 Results figures should weigh them with the loss and margin figures. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Suven Life Sciences Q2 Results FY27
What are Suven Life Sciences Q2 Results FY27?
Ans. Suven Life Sciences Q2 Results FY27 cover July to September 2026, with consolidated revenue of Rs 1.20 Cr and a net loss of Rs 106.94 Cr. Alongside this, the Financial Highlights table sets both against the year-earlier quarter.
What is the results date for Suven Life Sciences Q2 Results FY27?
Ans. The results date for Suven Life Sciences Q2 Results FY27 is 5 November 2026. This date appears in the Quick Answer and again in the opening paragraph of the article.
What revenue was reported in Suven Life Sciences Q2 Results FY27?
Ans. Suven Life Sciences reported revenue of Rs 1.20 Cr in Suven Life Sciences Q2 Results FY27, compared with Rs 0.92 Cr a year earlier. The Performance Analysis explains how this fits with the loss.
What net profit was reported in Suven Life Sciences Q2 Results FY27?
Ans. Suven Life Sciences Q2 Results FY27 show a net loss of Rs 106.94 Cr, against a net loss of Rs 77.31 Cr a year earlier. So the loss widened, as the Performance Analysis section shows.
How much YoY growth did revenue show in Suven Life Sciences Q2 Results FY27?
Ans. Revenue showed YoY growth of 30.43% in Suven Life Sciences Q2 Results FY27, moving from Rs 0.92 Cr to Rs 1.20 Cr. This growth is described in the Key Business Factors section.
Did net profit rise or fall in Suven Life Sciences Q2 Results?
Ans. Net profit fell YoY in the Suven Life Sciences Q2 Results, with the net loss moving from Rs 77.31 Cr to Rs 106.94 Cr. Compared with revenue growth of 30.43%, this is covered in the Key Takeaways section.
What was the Operating Profit in Suven Life Sciences Q2 Results FY27?
Ans. Operating Profit in Suven Life Sciences Q2 Results FY27 was a loss of Rs 110.92 Cr, against a loss of Rs 79.77 Cr a year earlier. This line is explained in the Performance Analysis section.
Are Suven Life Sciences Q2 Results consolidated results or standalone results?
Ans. The Suven Life Sciences Q2 Results are consolidated results, declared on a Consolidated basis on 5 November 2026. This basis is stated in the Quick Answer and used for every figure in the article.
What business factors shaped Suven Life Sciences Q2 Results FY27?
Ans. The disclosed factors are revenue growth of 30.4% YoY, a debt-to-assets ratio of 0.00 in FY26 and a return on capital employed of -78.71%. The Key Business Factors section describes each one.
What are the key risks after Suven Life Sciences Q2 Results FY27?
Ans. The risks after Suven Life Sciences Q2 Results FY27 are the net loss of Rs 106.94 Cr, a net profit margin of -8911.7% and low returns on equity and capital employed. Each one appears in the Key Risks section.
What is the outlook after Suven Life Sciences Q2 Results?
Ans. FY27 full-year consolidated results after the Suven Life Sciences Q2 Results will depend on the quarters still to be declared. This means the Outlook section links any view to later declarations only.
Where can I find the complete Suven Life Sciences Q2 Results FY27 data?
Ans. The complete Suven Life Sciences Q2 Results FY27 figures for revenue, Operating Profit and net profit sit in the Financial Highlights table of this article. Alongside this, the Univest Screener lets readers follow later filings.
